Sanofi (NASDAQ:SNY) Shares Sold by GC Wealth Management RIA LLC

GC Wealth Management RIA LLC cut its holdings in shares of Sanofi (NASDAQ:SNY) by 16.3% in the 4th quarter, Holdings Channel reports. The firm owned 10,758 shares of the company’s stock after selling 2,095 shares during the period. GC Wealth Management RIA LLC’s holdings in Sanofi were worth $519,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Synergy Asset Management LLC acquired a new stake in Sanofi during the fourth quarter valued at approximately $25,000. McClarren Financial Advisors Inc. lifted its stake in Sanofi by 952.6% during the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock valued at $28,000 after purchasing an additional 543 shares during the last quarter. Sunbelt Securities Inc. lifted its stake in Sanofi by 72.1% during the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock valued at $43,000 after purchasing an additional 313 shares during the last quarter. Sierra Ocean LLC acquired a new stake in shares of Sanofi during the fourth quarter valued at approximately $44,000. Finally, Versant Capital Management Inc acquired a new stake in shares of Sanofi during the fourth quarter valued at approximately $54,000. 14.04% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on SNY shares. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Finally, StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Two research analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Sanofi presently has an average rating of “Buy” and a consensus target price of $60.00.

Sanofi Stock Down 1.0 %

Sanofi stock opened at $58.74 on Wednesday. The firm has a market cap of $149.07 billion, a PE ratio of 23.59, a P/E/G ratio of 1.01 and a beta of 0.58. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. The firm’s 50 day moving average price is $53.08 and its two-hundred day moving average price is $52.78. Sanofi has a twelve month low of $45.22 and a twelve month high of $60.12.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, research analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.